These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
516 related articles for article (PubMed ID: 25529354)
1. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization. Wang W; Tang Y; Li J; Jiang L; Jiang Y; Su X Cancer Cytopathol; 2015 Feb; 123(2):117-22. PubMed ID: 25529354 [TBL] [Abstract][Full Text] [Related]
2. Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer. Zhou J; Yao H; Zhao J; Zhang S; You Q; Sun K; Zou Y; Zhou C; Zhou J Histopathology; 2015 Jun; 66(7):949-54. PubMed ID: 25257756 [TBL] [Abstract][Full Text] [Related]
3. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC). Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969 [TBL] [Abstract][Full Text] [Related]
4. Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods. Liu L; Zhan P; Zhou X; Song Y; Zhou X; Yu L; Wang J PLoS One; 2015; 10(3):e0117032. PubMed ID: 25785456 [TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200 [TBL] [Abstract][Full Text] [Related]
6. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552 [TBL] [Abstract][Full Text] [Related]
7. Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer. Zhong J; Li X; Bai H; Zhao J; Wang Z; Duan J; An T; Wu M; Wang Y; Wang S; Wang J Cytopathology; 2016 Dec; 27(6):433-443. PubMed ID: 27060609 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695 [TBL] [Abstract][Full Text] [Related]
9. [A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens]. Wang Z; Wu X; Shi Y; Han X; Cheng G; Li L; Mu X; Zhang Y; Cui D; Zhang L; Fan Z; Zhu G; Ma L; Yang L; Di J; Liu D Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):742-8. PubMed ID: 26813592 [TBL] [Abstract][Full Text] [Related]
10. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. von Laffert M; Warth A; Penzel R; Schirmacher P; Kerr KM; Elmberger G; Schildhaus HU; Büttner R; Lopez-Rios F; Reu S; Kirchner T; Pauwels P; Specht K; Drecoll E; Höfler H; Aust D; Baretton G; Bubendorf L; Stallmann S; Fisseler-Eckhoff A; Soltermann A; Tischler V; Moch H; Penault-Llorca F; Hager H; Schäper F; Lenze D; Hummel M; Dietel M J Thorac Oncol; 2014 Nov; 9(11):1685-92. PubMed ID: 25436802 [TBL] [Abstract][Full Text] [Related]
11. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma. Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128 [TBL] [Abstract][Full Text] [Related]
12. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086 [TBL] [Abstract][Full Text] [Related]
13. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247 [TBL] [Abstract][Full Text] [Related]
14. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. Thorne-Nuzzo T; Williams C; Catallini A; Clements J; Singh S; Amberson J; Dickinson K; Gatalica Z; Ho SN; Loftin I; McElhinny A; Towne P J Thorac Oncol; 2017 May; 12(5):804-813. PubMed ID: 28147239 [TBL] [Abstract][Full Text] [Related]
15. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803 [TBL] [Abstract][Full Text] [Related]
16. A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens. Lung J; Lin YC; Hung MS; Jiang YY; Lee KD; Lin PY; Tsai YH Lung Cancer; 2016 Apr; 94():114-20. PubMed ID: 26973216 [TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR. Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. Zhang YG; Jin ML; Li L; Zhao HY; Zeng X; Jiang L; Wei P; Diao XL; Li X; Cao Q; Tian XX PLoS One; 2013; 8(5):e64821. PubMed ID: 23741400 [TBL] [Abstract][Full Text] [Related]
20. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance. Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]